Arrowhead Research Corp. (ARWR)
-NasdaqCM 2.13 
0.18(7.79%) 3:59PM EDT
| Prev Close: | 2.31 |
|---|
| Open: | 2.22 |
|---|
| Bid: | 2.13 x 900 |
|---|
| Ask: | 2.15 x 500 |
|---|
| 1y Target Est: | 4.00 |
|---|
| Beta: | 1.75 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.11 - 2.30 |
|---|
| 52wk Range: | 1.65 - 4.50 |
|---|
| Volume: | 118,730 |
|---|
| Avg Vol (3m): | 131,662 |
|---|
| Market Cap: | 66.68M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.82 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ARROWHEAD RESEARCH CORP FinancialsEDGAR Online Financials(Fri, May 17)
- Arrowhead to Present at Upcoming Scientific ConferencesBusiness Wire(Mon, May 13)
- Arrowhead Research's CEO Discusses F2Q13 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Arrowhead Reports Fiscal 2013 Second Quarter Financial ResultsBusiness Wire(Thu, May 9)
- ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EEDGAR Online(Thu, May 9)
- Q2 2013 ARROWHEAD RESH CORP Earnings Release - Time Not SuppliedCCBN(Thu, May 9)
- Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide BackboneBusiness Wire(Tue, May 7)
- Arrowhead Closes $36 Million Private OfferingBusiness Wire(Mon, May 6)
- Arrowhead to Report Fiscal 2013 Second Quarter Financial ResultsBusiness Wire(Thu, May 2)
- ARROWHEAD RESEARCH CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. orEDGAR Online(Tue, Apr 30)
- 5 Health Care Stocks Under $10 to Watchat TheStreet(Tue, Apr 30)
- Arrowhead Prices $36 Million Private OfferingBusiness Wire(Mon, Apr 29)
- Arrowhead to Present at Master Investor 2013Business Wire(Wed, Apr 24)
- Arrowhead to Present at Needham Healthcare ConferenceBusiness Wire(Wed, Apr 24)
- ARROWHEAD RESEARCH CORP Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Mon, Mar 25)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 245.61 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Sep-13)
: | -0.96 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection.
View More